HistoSonics is taking histotripsy beyond liver tumors. Kidney cancer care may be the next credibility test.
HistoSonics has liver clearance. Kidney tumors are the harder test, where non-invasive ambition must meet regulatory and clinical proof.
Did Aurie just crack the one-use catheter problem hospitals avoided for decades?
Single-use catheters finally face a regulated reuse challenge. Aurie’s FDA De Novo win could shift urology device economics.
Can Biozen turn cuffless blood pressure from medtech promise into clinical reality?
Cuffs are accurate but inconvenient. Biozen’s FDA-cleared BP1000 tests whether fingertip blood pressure checks can change hypertension care.
How Envoy Medical, Inc.’s FDA pathway could influence the future of implantable hearing systems
Could fully implanted cochlear implants transform hearing restoration? Explore the regulatory, clinical, and market implications now.
Can Mevion’s S250-FIT make proton therapy practical for more cancer centers?
Proton therapy has long had an infrastructure problem. Mevion’s S250-FIT asks whether existing LINAC vaults can change that.
Phillips Medisize targets formulation-device risk as inhaled therapies grow more complex
Inhalers are getting smarter, but complexity can backfire. Phillips Medisize is betting DPI success starts with patient-centric design.
Why Sensus Healthcare’s SkinCure resolution matters for superficial radiotherapy growth
Sensus settled the dispute, but the harder test is SRT adoption. Can reimbursement momentum turn into durable medtech growth?
Could Co-Diagnostics’ Saudi manufacturing move strengthen its molecular diagnostics strategy?
Saudi localization gives Co-Diagnostics a new opening. The test is whether CoMira can turn a factory lease into diagnostics traction.
Why BD’s Wellstar partnership could reshape medication delivery inside hospitals
Hospitals need safer medication delivery, not more disconnected tech. BD and Wellstar are testing whether AI can close that workflow gap.
Medtronic just cleared a key ECMO transport hurdle, but hospitals still face the harder test
ECMO transport is a clinical weak point. Medtronic’s VitalFlow CE mark tests whether device mobility can strengthen critical care networks.